Suppr超能文献

口服 P22 噬菌体尾刺蛋白可减少鸡体内沙门氏菌的定植:一种新型抗细菌感染疗法的前景。

Orally administered P22 phage tailspike protein reduces salmonella colonization in chickens: prospects of a novel therapy against bacterial infections.

机构信息

Institute for Biological Sciences, National Research Council of Canada, Ottawa, Canada.

出版信息

PLoS One. 2010 Nov 22;5(11):e13904. doi: 10.1371/journal.pone.0013904.

Abstract

One of the major causes of morbidity and mortality in man and economically important animals is bacterial infections of the gastrointestinal (GI) tract. The emergence of difficult-to-treat infections, primarily caused by antibiotic resistant bacteria, demands for alternatives to antibiotic therapy. Currently, one of the emerging therapeutic alternatives is the use of lytic bacteriophages. In an effort to exploit the target specificity and therapeutic potential of bacteriophages, we examined the utility of bacteriophage tailspike proteins (Tsps). Among the best-characterized Tsps is that from the Podoviridae P22 bacteriophage, which recognizes the lipopolysaccharides of Salmonella enterica serovar Typhimurium. In this study, we utilized a truncated, functionally equivalent version of the P22 tailspike protein, P22sTsp, as a prototype to demonstrate the therapeutic potential of Tsps in the GI tract of chickens. Bacterial agglutination assays showed that P22sTsp was capable of agglutinating S. Typhimurium at levels similar to antibodies and incubating the Tsp with chicken GI fluids showed no proteolytic activity against the Tsp. Testing P22sTsp against the three major GI proteases showed that P22sTsp was resistant to trypsin and partially to chymotrypsin, but sensitive to pepsin. However, in formulated form for oral administration, P22sTsp was resistant to all three proteases. When administered orally to chickens, P22sTsp significantly reduced Salmonella colonization in the gut and its further penetration into internal organs. In in vitro assays, P22sTsp effectively retarded Salmonella motility, a factor implicated in bacterial colonization and invasion, suggesting that the in vivo decolonization ability of P22sTsp may, at least in part, be due to its ability to interfere with motility… Our findings show promise in terms of opening novel Tsp-based oral therapeutic approaches against bacterial infections in production animals and potentially in humans.

摘要

在人类和经济上重要的动物中,发病率和死亡率的主要原因之一是胃肠道(GI)tract 的细菌感染。由于抗生素耐药菌引起的难以治疗的感染的出现,需要替代抗生素治疗。目前,一种新兴的治疗替代方法是使用裂解噬菌体。为了利用噬菌体的靶向特异性和治疗潜力,我们研究了噬菌体尾刺蛋白(Tsps)的用途。在最好表征的 Tsps 中,有来自 Podoviridae P22 噬菌体的 Tsp,它可以识别肠炎沙门氏菌的脂多糖。在这项研究中,我们利用截短的、功能等效的 P22 尾刺蛋白 P22sTsp 作为原型,证明了 Tsps 在鸡的胃肠道中的治疗潜力。细菌凝集实验表明,P22sTsp 能够与肠炎沙门氏菌凝集,水平与抗体相似,并且孵育 Tsp 与鸡 GI 液没有对 Tsp 的蛋白水解活性。对 P22sTsp 进行的三种主要 GI 蛋白酶测试表明,P22sTsp 对胰蛋白酶有抗性,对胰凝乳蛋白酶有部分抗性,但对胃蛋白酶敏感。然而,在口服制剂形式中,P22sTsp 对三种蛋白酶都有抗性。当口服给予鸡时,P22sTsp 显著降低了肠道中的沙门氏菌定植及其进一步穿透内部器官。在体外实验中,P22sTsp 有效地减缓了沙门氏菌的运动,这一因素与细菌定植和入侵有关,这表明 P22sTsp 的体内去定植能力至少部分是由于其干扰运动的能力...我们的发现表明,在针对生产动物和潜在人类的细菌感染方面,基于 Tsp 的新型口服治疗方法具有广阔的前景。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd2e/2989905/35fae301a168/pone.0013904.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验